Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib

被引：49

作者：

Alexandrescu, Doru T. ^{[1
]}

McClure, Rebecca ^{[2
]}

Farzanmehr, Haleh ^{[3
]}

Dasanu, Constantin A. ^{[4
]}

机构：

[1] Georgetown Univ, Washington Canc Inst, Washington, DC 20057 USA

[2] Washington Hosp Ctr, Dept Pathol, Washington, DC 20010 USA

[3] Mayo Clin, Rochester, MN USA

[4] Grp Hlth, Dept Hematol Oncol, Seattle, WA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 24期

关键词：

D O I：

10.1200/JCO.2008.18.3525

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：4047 / 4048

页数：2

共 3 条

[1]

Knox JJ, 2007, J CLIN ONCOL, V25

[2]

Sunitinib in patients with metastatic renal cell carcinoma [J].

Motzer, Robert J. ;

Rini, Brian I. ;

Bukowski, Ronald M. ;

Curti, Brendan D. ;

George, Daniel J. ;

Hudes, Gary R. ;

Redman, Bruce G. ;

Margolin, Kim A. ;

Merchan, Jaime R. ;

Wilding, George ;

Ginsberg, Michelle S. ;

Bacik, Jennifer ;

Kim, Sindy T. ;

Baum, Charles M. ;

Michaelson, M. Dror .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2516-2524

[3]

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib [J].

Porta, C. ;

Paglino, C. ;

Imarisio, I. ;

Bonomi, L. .

CLINICAL AND EXPERIMENTAL MEDICINE, 2007, 7 (04) :127-134

← 1 →